J&J-Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

Group 1 - Johnson & Johnson's stock closed at $150.47, down 1.24%, underperforming the S&P 500's gain of 0.61% on the same day [1] - Over the past month, Johnson & Johnson's stock has decreased by 3.78%, compared to a 1.45% loss in the Medical sector and a 5.79% gain in the S&P 500 [1] Group 2 - The upcoming earnings disclosure is expected to show an EPS of$ 1.99, reflecting a 13.1% decline year-over-year, while revenue is projected at $22.54 billion, a 5.37% increase from the previous year [2] - For the full year, earnings are estimated at$ 9.93 per share and revenue at $88.84 billion, indicating a 0.1% increase in earnings but a 4.49% decrease in revenue compared to the prior year [3] Group 3 - Recent adjustments to analyst estimates for Johnson & Johnson are important as they reflect short-term business trends, with positive revisions indicating a favorable outlook on the company's health and profitability [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently places Johnson & Johnson at 3 (Hold), with a steady EPS estimate over the past month [6] Group 4 - Johnson & Johnson has a Forward P/E ratio of 15.34, which is higher than the industry average of 14.51, and a PEG ratio of 2.71 compared to the industry's average of 1.49 [7] - The Large Cap Pharmaceuticals industry, which includes Johnson & Johnson, has a Zacks Industry Rank of 156, placing it in the bottom 38% of over 250 industries [8]